# Compassionate Use of Ubamatamab

> **NCT07502716** · — · AVAILABLE · sponsor: **Regeneron Pharmaceuticals**

## Conditions studied

- Renal Medullary Carcinoma (RMC)
- Epithelioid Sarcoma

## Interventions

- **DRUG:** ubamatamab

## Key facts

- **NCT ID:** NCT07502716
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502716, "Compassionate Use of Ubamatamab". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07502716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*